Literature DB >> 17636694

WITHDRAWN: Low level laser therapy (Classes III) for treating osteoarthritis.

L Brosseau1, V Robinson, G Wells, R Debie, A Gam, K Harman, M Morin, B Shea, P Tugwell.   

Abstract

BACKGROUND: Osteoarthritis (OA) affects a large portion of the population. Low Level Laser Therapy (LLLT) is a light source that generates extremely pure light, of a single wavelength. The effect is not thermal, but rather related to photochemical reactions in the cells. LLLT was introduced as an alternative non-invasive treatment for OA about 30 years ago, but its effectiveness has to be examined more closely, especially in the treatment of OA.
OBJECTIVES: To assess the effectiveness of class III LLLT for osteoarthritis when irradiation is directed at the osteoarthritic joint capsule. SEARCH STRATEGY: Searches were conducted in the following databases: MEDLINE, EMBASE, the Cochrane Musculoskeletal registry, the Rehabilitation and Related Therapies field registry and the Cochrane Controlled Trials Register up to May, 2005. SELECTION CRITERIA: Following an a prior protocol, only controlled clinical trials of LLLT for the treatment of patients with a clinical diagnosis of OA were eligible. Abstracts lacking data were excluded unless further data could be obtained from the authors. DATA COLLECTION AND ANALYSIS: Two reviewers independently selected trials and extracted data using predetermined forms. A fixed effects model was used throughout for continuous variables, except where heterogeneity existed; in which case, a random effects model was used. Results were analyzed as weighted mean differences (WMD) with 95% confidence intervals (CI), whereas the difference between the treatment and control groups was weighted by the inverse of the variance. Standardized mean differences (SMD) were calculated by dividing the difference between treatment and control by the baseline variance, and were used in the analysis of pain because different scales were used to measure it. Dichotomous outcomes were analyzed with relative risk (RR). MAIN
RESULTS: Eight trials were included with 233 patients randomized to laser and 172 patients to placebo laser. Treatment duration ranged from two to six weeks. Pain was assessed in seven trials. When the results were pooled from different pain scales used in these seven trials, a statistically significant difference in favor of laser treatment was found with a SMD of -0.28 (95% CI: -0.48 to -0.09). One of these studies also measured pain during movement and found a statistically significant difference in favor of laser treatment with a WMD of -1.16 (95% CI: -2.02 to -0.30). Two studies found significant results for increased knee range of motion. Two others studies found a statistically significant difference in favor of laser treatment for patient-assessed global disease activity with laser compared to placebo (RR 1.70, 95%CI: 1.1. to 2.63). One trial evaluated the effectiveness of laser treatment in temporomandibular joint OA and found a statistically significant difference (WMD 38.69, 95% CI: 29.25 to 48.13) using the change in VAS score to measure pain. One study found a statistically significant difference in favor of laser treatment at the end of treatment and at 4 and 8 weeks post-treatment for morning stiffness. Other outcome measures of joint tenderness and strength did not yield significant differences. AUTHORS'
CONCLUSIONS: Five trials included in this review showed a statistically significant difference favoring laser treatment when compared to placebo for at least one outcome measure. Three trials did not report beneficial effects. The varying results of these trials may be due to the method of laser application and/or other features of LLLT application. Clinicians and researchers should consistently report the characteristics of LLLT devices and application techniques used. New trials on LLLT should make use of standardized, validated outcomes. There is clearly a need to investigate the effects of different dosages on LLLT effectiveness for OA in future randomized, controlled clinical trials. Also, more studies should be done to investigate the anti-inflammatory action of laser as well as the appropriate parameters needed to achieve an anti-inflammatory effect.

Entities:  

Mesh:

Year:  2007        PMID: 17636694     DOI: 10.1002/14651858.CD002046.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  6 in total

Review 1.  Obstacles to the Prescription and Use of Opioids.

Authors:  Rachel S Wallwork; Fallon E Chipidza; Theodore A Stern
Journal:  Prim Care Companion CNS Disord       Date:  2016-02-18

2.  Low-level laser therapy (LLLT; 780 nm) acts differently on mRNA expression of anti- and pro-inflammatory mediators in an experimental model of collagenase-induced tendinitis in rat.

Authors:  Débora Pires; Murilo Xavier; Tiago Araújo; José Antônio Silva; Flavio Aimbire; Regiane Albertini
Journal:  Lasers Med Sci       Date:  2010-08-25       Impact factor: 3.161

3.  Five-day, low-level laser therapy for sports-related lower extremity periostitis in adult men: a randomized, controlled trial.

Authors:  Cheng-Chiang Chang; Chih-Hung Ku; Wei-Chun Hsu; Yu-An Hu; Jia-Fwu Shyu; Shin-Tsu Chang
Journal:  Lasers Med Sci       Date:  2014-03-13       Impact factor: 3.161

4.  Conservative management of posterior interosseous neuropathy in an elite baseball pitcher's return to play: a case report and review of the literature.

Authors:  Andrew Robb; Sandy Sajko
Journal:  J Can Chiropr Assoc       Date:  2009-12

5.  Patterns of traditional chinese medicine diagnosis in thermal laser acupuncture treatment of knee osteoarthritis.

Authors:  Lizhen Wang; Fan Wu; Ling Zhao; Haimeng Zhang; Xueyong Shen; Yi Huang; Lixing Lao
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-28       Impact factor: 2.629

Review 6.  Molecular and Cellular Mechanisms of Arthritis in Children and Adults: New Perspectives on Applied Photobiomodulation.

Authors:  Laura Marinela Ailioaie; Gerhard Litscher
Journal:  Int J Mol Sci       Date:  2020-09-08       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.